HK1103355A1 - Novel tellurium compounds and their use as immunomodulators - Google Patents
Novel tellurium compounds and their use as immunomodulatorsInfo
- Publication number
- HK1103355A1 HK1103355A1 HK07111672.5A HK07111672A HK1103355A1 HK 1103355 A1 HK1103355 A1 HK 1103355A1 HK 07111672 A HK07111672 A HK 07111672A HK 1103355 A1 HK1103355 A1 HK 1103355A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunomodulators
- tellurium compounds
- novel
- novel tellurium
- compounds
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 150000003498 tellurium compounds Chemical class 0.000 title 1
- 102100035904 Caspase-1 Human genes 0.000 abstract 2
- 108090000426 Caspase-1 Proteins 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229910052714 tellurium Inorganic materials 0.000 abstract 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C395/00—Compounds containing tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61066004P | 2004-09-17 | 2004-09-17 | |
PCT/IL2005/000989 WO2006030437A2 (en) | 2004-09-17 | 2005-09-15 | Novel tellurium compounds and their use as immunomodulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1103355A1 true HK1103355A1 (en) | 2007-12-21 |
Family
ID=35985262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07111672.5A HK1103355A1 (en) | 2004-09-17 | 2007-10-30 | Novel tellurium compounds and their use as immunomodulators |
Country Status (11)
Country | Link |
---|---|
US (5) | US7709524B2 (es) |
EP (3) | EP1791535B1 (es) |
JP (1) | JP2008513439A (es) |
AT (1) | ATE402709T1 (es) |
AU (1) | AU2005283719A1 (es) |
CA (3) | CA2580642C (es) |
DE (1) | DE602005008622D1 (es) |
ES (2) | ES2312012T3 (es) |
HK (1) | HK1103355A1 (es) |
PT (1) | PT1796660T (es) |
WO (3) | WO2006030439A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005060341A2 (en) | 2003-12-18 | 2005-07-07 | Biomas, Ltd | Tellurium derivatives for prevention and treatment of neurodegenerative processes |
US9011933B2 (en) * | 2004-01-22 | 2015-04-21 | Biomas Ltd. | Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds |
US20080260770A1 (en) * | 2004-09-17 | 2008-10-23 | Biomas Ltd. | Use of Tellurium Compounds as Adjuvants |
EP1791535B1 (en) | 2004-09-17 | 2008-07-30 | BioMAS Ltd. | Novel tellurium compounds and their use as immunomodulators |
WO2006075314A2 (en) | 2005-01-11 | 2006-07-20 | Jemtex Ink Jet Printing Ltd. | Inkjet printer and method of controlling same |
EP1924254A4 (en) * | 2005-09-15 | 2011-01-19 | Biomas Ltd | USE OF TELLURO COMPOUNDS FOR PROTECTION AGAINST ULTRAVIOLET RADIATION |
NZ573248A (en) * | 2006-06-01 | 2011-01-28 | Nobera Pharma Sl | Use of allopurinol (1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) for the treatment of palmar plantar erythrodysesthesia |
EP1862166A1 (en) * | 2006-06-01 | 2007-12-05 | Yolanda Rodemer | Use of allopurinol for the treatment of palmar plantar erythrodysesthesia |
JP2010502764A (ja) | 2006-09-11 | 2010-01-28 | バイオマス リミテッド | テルル含有化合物の局所製剤 |
CA2705944C (en) | 2007-11-23 | 2017-10-24 | Biomas Ltd. | Methods and compositions for inhibiting integrins using tellurium-containing compounds |
WO2009066301A2 (en) * | 2007-11-23 | 2009-05-28 | Biomas Ltd. | Methods and compositions for treating pox virus with tellurium-containing compounds |
WO2010079488A1 (en) * | 2009-01-08 | 2010-07-15 | Biomas Ltd. | Tellurium-containing compounds for affecting male's fertility following chemotherapy and/or radiotherapy |
WO2010079489A1 (en) * | 2009-01-08 | 2010-07-15 | Biomas Ltd. | Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy |
EP2246057A1 (en) | 2009-04-29 | 2010-11-03 | Nobera Pharma, S.L. | Use of allopurinol for the treatment of hand foot skin reaction |
WO2010146547A1 (en) * | 2009-06-16 | 2010-12-23 | Biomas Ltd. | Tellurium-containing compounds for facilitating transplantation |
WO2011041584A2 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
WO2012065065A1 (en) * | 2010-11-12 | 2012-05-18 | Follica, Inc. | Methods and compositions for modulating hair growth, wound healing and scar revision |
CA2819859A1 (en) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
KR20180110141A (ko) | 2016-02-18 | 2018-10-08 | 엔리벡스 테라퓨틱스 리미티드 | 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합 |
WO2018199000A1 (ja) * | 2017-04-28 | 2018-11-01 | 国立大学法人京都大学 | 有機テルル化合物及びその製造方法、リビングラジカル重合開始剤、ビニル重合体の製造方法、並びにビニル重合体 |
KR20240033119A (ko) | 2017-06-30 | 2024-03-12 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 모발 성장을 조절하기 위한 조성물 및 방법 |
CA3077359A1 (en) * | 2017-09-29 | 2019-04-04 | The Regents Of The University Of California | Compositions and methods for modulating hair growth |
JP2021042161A (ja) * | 2019-09-11 | 2021-03-18 | 国立大学法人東海国立大学機構 | 脱毛剤、脱毛モデル動物及び白髪モデル動物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3369550A (en) | 1967-02-17 | 1968-02-20 | Thomas A. Armao | Cryogenic clamps |
GB1427415A (en) | 1973-09-21 | 1976-03-10 | Armao T A | Cryosurgical instruments |
US4139619A (en) * | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
US4962207A (en) | 1985-09-30 | 1990-10-09 | Bar-Ilan University | Organic derivatives of tellurium and selenium |
US5102908A (en) * | 1985-03-15 | 1992-04-07 | Michael Albeck | Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives |
US4761490A (en) | 1985-03-15 | 1988-08-02 | Bar-Ilan University | Organic derivatives of tellurium and selenium and their use to stimulate cytokine production |
US5093135A (en) * | 1985-09-30 | 1992-03-03 | Michael Albeck | Compounds for the induction of in vivo and in vitro production of cytokines |
US4752614A (en) * | 1985-09-30 | 1988-06-21 | Bar-Ilan University | Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines |
US4764461A (en) * | 1985-09-30 | 1988-08-16 | Bar-Ilan University | Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines |
US4929739A (en) * | 1988-03-24 | 1990-05-29 | Bar-Ilan University | Complexes of tellurium and selenium derivatives |
DE4007473A1 (de) | 1990-03-09 | 1991-09-12 | Tomsk G Med I | Kryoskalpell |
US5271925A (en) * | 1990-03-09 | 1993-12-21 | Benjamin Sredni | Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound |
US5213899A (en) * | 1990-12-17 | 1993-05-25 | General Electric Company | Room temperature vulcanizable silicone compositions |
US5262149A (en) * | 1992-08-13 | 1993-11-16 | Benjamin Sredni | Method of treating or preventing alopecia |
CA2196063A1 (en) | 1994-09-01 | 1996-03-07 | Ching-Chiang Su | Cosolvent parenteral formulation of tirilazad |
US5576347A (en) * | 1994-11-14 | 1996-11-19 | Sredni; Benjamin | Method of treating gastric ulcers |
US5654328A (en) | 1994-12-15 | 1997-08-05 | Sredni; Benjamin | Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds |
JPH10510812A (ja) | 1994-12-15 | 1998-10-20 | ベーカー ノートン ファーマスーティカルズ、インコーポレーテッド | タクサン化合物およびテルルおよび/またはセレン化合物の併用により腫瘍の発育を減少させるための方法および組成物 |
NZ528282A (en) * | 1998-03-19 | 2005-05-27 | Vertex Pharma | Interleukin-1 beta converting enzyme inhibitors |
US6428534B1 (en) | 1999-02-24 | 2002-08-06 | Cryovascular Systems, Inc. | Cryogenic angioplasty catheter |
BR0009610A (pt) * | 1999-04-09 | 2002-02-13 | Cytovia Inc | Inibidores de caspase e uso dos mesmos |
CA2380935A1 (en) * | 2000-05-23 | 2001-11-29 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
DE60131160T2 (de) * | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
US6747008B1 (en) * | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
WO2001098325A1 (en) * | 2000-06-19 | 2001-12-27 | University Of Southern California | Methods for treating and preventing alopecia |
WO2002042278A2 (en) * | 2000-11-21 | 2002-05-30 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
US20030148970A1 (en) | 2001-01-12 | 2003-08-07 | Besterman Jeffrey M. | Methods for specifically inhibiting histone deacetylase-4 |
CA2447999C (en) * | 2001-05-23 | 2011-04-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
US6472381B1 (en) * | 2001-10-12 | 2002-10-29 | Biomas Inc. | Method of treating psoriasis |
IL146694A (en) * | 2001-11-22 | 2010-12-30 | Biomas Ltd | Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament |
AR040350A1 (es) * | 2002-06-28 | 2005-03-30 | Vertex Pharma | Inhibidores de caspasa y usos de los mismos |
CA2511235A1 (en) * | 2002-12-20 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors |
WO2005060341A2 (en) | 2003-12-18 | 2005-07-07 | Biomas, Ltd | Tellurium derivatives for prevention and treatment of neurodegenerative processes |
US9474453B2 (en) | 2004-09-15 | 2016-10-25 | Itamar Medical Ltd. | Measuring blood flow and venous capacitance |
US20080260770A1 (en) * | 2004-09-17 | 2008-10-23 | Biomas Ltd. | Use of Tellurium Compounds as Adjuvants |
EP1791535B1 (en) * | 2004-09-17 | 2008-07-30 | BioMAS Ltd. | Novel tellurium compounds and their use as immunomodulators |
-
2005
- 2005-09-15 EP EP05779419A patent/EP1791535B1/en not_active Not-in-force
- 2005-09-15 WO PCT/IL2005/000991 patent/WO2006030439A2/en active Application Filing
- 2005-09-15 WO PCT/IL2005/000990 patent/WO2006030438A2/en active Application Filing
- 2005-09-15 US US11/663,032 patent/US7709524B2/en not_active Expired - Fee Related
- 2005-09-15 CA CA2580642A patent/CA2580642C/en not_active Expired - Fee Related
- 2005-09-15 EP EP05784166A patent/EP1802292A4/en not_active Withdrawn
- 2005-09-15 ES ES05779419T patent/ES2312012T3/es active Active
- 2005-09-15 US US11/663,031 patent/US7652065B2/en not_active Expired - Fee Related
- 2005-09-15 ES ES05779639.3T patent/ES2614113T3/es active Active
- 2005-09-15 CA CA2580643A patent/CA2580643C/en not_active Expired - Fee Related
- 2005-09-15 US US11/662,743 patent/US20090269418A1/en not_active Abandoned
- 2005-09-15 EP EP05779639.3A patent/EP1796660B1/en not_active Not-in-force
- 2005-09-15 WO PCT/IL2005/000989 patent/WO2006030437A2/en active IP Right Grant
- 2005-09-15 CA CA002580804A patent/CA2580804A1/en not_active Abandoned
- 2005-09-15 AT AT05779419T patent/ATE402709T1/de not_active IP Right Cessation
- 2005-09-15 JP JP2007531953A patent/JP2008513439A/ja active Pending
- 2005-09-15 DE DE602005008622T patent/DE602005008622D1/de active Active
- 2005-09-15 AU AU2005283719A patent/AU2005283719A1/en not_active Abandoned
- 2005-09-15 PT PT57796393T patent/PT1796660T/pt unknown
-
2007
- 2007-10-30 HK HK07111672.5A patent/HK1103355A1/xx not_active IP Right Cessation
-
2009
- 2009-12-02 US US12/629,071 patent/US20100081623A1/en not_active Abandoned
-
2010
- 2010-03-22 US US12/728,362 patent/US8623908B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1103355A1 (en) | Novel tellurium compounds and their use as immunomodulators | |
MXPA05008246A (es) | Inhibidores de histona desacetilasa. | |
SG166770A1 (en) | Use of adipose tissue-derived stromal stem cells in treating fistula | |
WO2005117846A3 (en) | Ice inhibitors for the treatment of autoinflammatory diseases | |
SG10201805844QA (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
MXPA04002397A (es) | Inhibidores de histona deacetilasa. | |
EP1841463A4 (en) | METHODS AND COMPOSITIONS FOR TREATING, INHIBITING AND REVERTING INTERVERTEBRAL DISCOPATHIES | |
AU2001248701A1 (en) | Inhibitors of histone deacetylase | |
TWI367886B (en) | Proteasome inhibitors and methods of using the same | |
MX2010006154A (es) | Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa. | |
WO2006133403A3 (en) | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival | |
WO2007111948A3 (en) | Inhibitors of protein prenyltransferases | |
HK1091839A1 (en) | Proteasome inhibitors and methods of using the same | |
EP2573069A3 (en) | Inhibitors of histone deacetylase and prodrugs thereof | |
HK1089153A1 (en) | Proteasome inhibitors and methods of using the same | |
IL178968A0 (en) | Novel pyridazinone derivatives as inhibitors of cdk2 | |
TW200745059A (en) | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | |
TW200621744A (en) | Mercaptoamides as histone deacetylase inhibitors | |
AU2003301903A8 (en) | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
MY162518A (en) | Proteasome inhibitors and methods of using the same | |
WO2006104751A3 (en) | Methods and compositions for modulating rho-mediated gene transcription | |
ATE435246T1 (de) | Wässrige behandlungszusammensetzungen und polymere zur verwendung darin | |
WO2023114516A3 (en) | Cell-permeant inhibitors of viral cysteine proteases | |
UA27355U (en) | Method for purification of natural and after-purification of potable water | |
TW200602047A (en) | Inhibitors of histone deacetylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210915 |